SMS Pharmaceuticals Limited
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.
What SMS files
- Others61
- Updates24
- Important24
- Investor Meet12
- Pledging11
- Board Meeting8
SMS Pharma's Q1FY27 revenue grew 6% YoY to ₹207 Cr, with PAT up 8% YoY to ₹20 Cr. EBITDA margin remained strong at 20%. Growth was broad-based across high-value APIs, led by Anti-diabetic (33% of revenue) and European markets (34%). The company is strategically investing in R&D, expanding its team...
SMS Pharma delivered a strong Q3FY26! Revenue leaped 21% YoY to ₹210 Cr, fueled by robust volume growth in key APIs. Profit After Tax (PAT) surged 29% YoY to ₹23.47 Cr, with 9-month PAT up an impressive 42%. Growth is powered by a ₹280 Cr capital expenditure program, on track...
**1. Business Performance:** SMS Pharma reported strong Q2FY26 results with revenue up 23% YoY to ₹242 Cr, EBITDA rising 54% to ₹48 Cr, and PAT jumping 80% to ₹25 Cr. EPS grew 70% to ₹2.84. H1FY26 also saw solid performance: revenue at ₹438 Cr (up 21%), EBITDA at ₹88 Cr...
Here's a summary of the attached investor presentation: **Financial Highlights:** SMS Pharmaceuticals reported robust Q1FY26: revenue reached ₹196 Cr (+19% YoY), PAT grew 24% YoY to ₹20.5 Cr, with EBITDA margin steady at 20%. EPS was ₹2.31. FY26 outlook maintains 20% revenue growth and 20% EBITDA margin. **Strategic Initiatives &...
**Financial Highlights:** In Q3FY25, revenue from operations reached ₹173.35 crore, marking a 7% year-over-year growth, primarily driven by strong volume across the product portfolio. EBITDA increased by 15% to ₹33.21 crore, with a margin of 19%, reflecting a slight improvement from 18% a year ago. Net Profit After Tax (PAT)...